The purpose of the present study was to determine the metabolism of olsalazine in the colon and the drug tolerance during longterm administration of high doses in colitis patients not satisfactorily treated with sulphasalazine -that is, in patients with UC or CC refractory to or intolerant of sulphasalazine. Luminal concentrations of prostaglandin E2 (PGE2) and leucotriene B4 (LTB4) were also determined during the treatment period to study whether these highly sensitive markers of disease activity'7 '" might predict the outcome of treatment.
Methods

PATIENTS
Patients fulfilling the following entry criteria were included in the study: (a) proven UC'9 or proven CC:"' (b) relapsing disease -that is, a relapse within the past six months, or chronic continuous disease activity-that is, absence of remission (definition: see below) for three months or more; (c) refractory to sulphasalazine -that is, relapsing disease despite maintenance treatment with sulphasalazine 2 g/day or chronic continuous disease despite treatment with glucocorticoids and sulphasalazine, or intolerant of sulphasalazine -that is, allergic to or otherwise intolerant of sulphasalazine.
Patients below 18 or above 80 years of age were excluded, as were women who were pregnant or lactating and those with childbearing potential not using oral contraception or an intrauterine device. Furthermore, patients with CC, who had also radiologically verified small bowel disease were excluded.
Each patient gave informed consent and the study was approved by the Ethical Committee of Funen and Vejle Counties.
EXPERIMENTAL DESIGN
The study design was open with an initial dose of 1 g/day (0.5 g bid) in sulphasalazine intolerant patients. In sulphasalazine refractory patients the initial dose was 2 g/day (1 g bid) with no washout period after cessation. The dose was gradually increased at the scheduled visits until the endpoint was reached -that is, sustained remission -as defined below, or drug intolerance occurred, or a maximum of 4 g/day (1 g qid) equivalent to approximately 10 g/day of sulphasalazine as regards 5-ASA on a molar basis. In patients on concomitant corticosteroids the dose was gradually tapered when clinically inactive disease (see below) occurred and, if possible, the administration was stopped.
A one year treatment period was planned including scheduled visits at two weeks and at two, four, six, eight, 10, and 12 months, in addition to inbetween visits, if needed. Before entry and at each visit the clinical disease activity was assessed (see below) and a laboratory screening was done. This included blood haemoglobin, reticulocyte count, erythrocyte sedimentation rate, leucocyte count, leucocyte differential count, platelet count, serum concentrations of Na, K, Ca, albumin, creatinine, urea, alanine aminotransferase, lactate dehydrogenase, alkaline phosphatase, bilirubin, and plasma prothrombin, in addition to urine analysis for protein and glucose and microscopy for erythrocytes, leucocytes, and casts.
Additional serum was obtained before the administration of the morning dose of olsalazine for determination of olsalazine, 5-ASA, and Ac-5-ASA.
Before entry, at the two weeks' visit, and at the six and 12 months' visits equilibrium in vivo dialysis of faeces'6 as well as equilibrium in vivo dialysis of rectum'7 were done before endoscopy of rectum and sigmoid colon with biopsies. The patients had been at a particular dose level of olsalazine for two weeks or more before these measurements were performed.
Olsalazine Determination of olsalazine, 5-ASA, and Ac-5-ASA in serum and faecal dialysates were done by high performance liquid chromatography (HPLC) as previously described.'6 The lower detection limits in serum and in faecal dialysates were I 0 imol/l and 6-0 [tmol/l, respectively. Prostaglandin E2 was measured by a radioimmunological method"4 validated by gas chromatography mass spectrometry2' and LTB4 by reversed phase HPLC. '7 These measurements were done blind and independent of the assessment of disease activity and clinicians were unaware of the results until the data had been completed.
REFLECTIONS ON SAMPLE SIZE
In planning the study it was considered relevant to compare colonic olsalazine metabolism and tolerance, (a) in patients with extensively located colitis and in patients with 'left-sided' colitis, (b) in sulphasalazine refractory patients and in sulphasalazine and the number of days of treatment) was 2-6 g/day (range 1-0-3-6 g/day). For the nine patients with CC the similar figures were 319 days (range 93-383 days) and 2-5 g/day (range 1-0-3-5 g/day). The treated with equal dosages of olsalazine, but the number of observations in the CC group precluded statistical comparison with the UC group. Concentrations of Ac-5-ASA in faecal dialysates were rather constant within the applied olsalazine dose range (from 1 g/day to 4 g/day), but concentrations of free 5-ASA, and thus also concentrations of total 5-ASA increased dose dependently (Table 3) . Olsalazine concentrations in faecal dialysates were low (Table 3) compared with those of the split product (5-ASA) and its metabolite (Ac-5-ASA). The efficacy of azoreduction was estimated by calculation of the 'split ratio' -that is, the ratio between molar concentrations in faecal dialysates of total 5-ASA and total 5-ASA+5-ASA contents in unsplit olsalazine, respectively. The median split ratio was 99*4% 
5-AMINOSALICYLIC ACID, AND ACETYL-5-AMINOSALICYLIC ACID IN SERUM
The average serum concentrations of olsalazine, 5-ASA, and Ac-5-ASA in each patient were calculated for each dosage of olsalazine. The results are given in Table 5 for patients with UC. Dose dependent increases in the levels of olsalazine and 5-ASA were observed within the whole dose range, but no further increase in serum concentrations of Ac-5-ASA occurred beyond a dose of olsalazine equal to 3 g/day (Table 5) . No statistically significant differences (p>005) were found between serum concentrations of olsalazine, 5-ASA, and Ac-5-ASA in patients with UC and CC, respectively, when treated with an equal dosage of olsalazine. Similarly, Table 5 Concentrations ofolsalazine, 5-ASA, and Ac-5-ASA in serum ofpatients with ulcerative colitis: average in each patientfor each dosage ofolsalazine no statistically significant differences (p>0-05) were found between levels of olsalazine in patients with active disease and patients in remission ( 
DIALYSATES
The trend in levels of PGE2 in faecal and rectal dialysates was a significant decrease with time in patients with UC, whether they were refractory to or intolerant of sulphasalazine (Table 6 ), whereas no decrease was disclosed in the levels of rectal LTB4.
Concentrations of PGE2 and LTB4 were significantly raised in patients with active UC (C1-C3) compared to those obtained in patients in remission (C0). (Table 6 ).
ESTIMATES ON EFFICACY
Thirteen patients with UC were regarded as treatment failures-that is, clinical and sigmoidoscopic remission was never obtained. This outcome was observed in one of eight patients intolerant of sulphasalazine and in 12 of 23 patients refractory to sulphasalazine (p=0-12, Fisher's exact test). In six cases the disease was 'left-sided', whereas seven cases had a pancolitis. In the remaining patients a relapse occurred on at least one occasion: four experienced a relapse on 1 g/day, two on 2 g/day, eight on 3 g/day, and two on 4 g/day.
All patients classified as treatment failures had been given the maximum dose of olsalazine of 4 g/day, except in three cases (Table 2 ; patient no 15, 31, 34), in whom drug intolerance occurred and all had been treated for the whole 12 months' period, except those who were withdrawn prematurely, as described above.
Five of the nine patients with CC were classified as treatment failures -that is, a CDAI <150, without sigmoidoscopic evidence of inflammation, was never obtained.
Discussion
Previous studies have shown that small intestinal absorption and metabolism of olsalazine is minimal and that a single oral dose is completely recovered from ileostomy fluid.-" In patients with inactive UC complete azoreduction of olsalazine occurs on 1 g bid and concentrations of 5-ASA in faecal dialysates, in fact, double when sulphasalazine is replaced by the same dose of olsalazine.'" Oral olsalazine 0-5 g bid appears more effective than placebo in preventing relapse in sulphasalazine intolerant patients27 and 1 g bid orally for two weeks is more effective than placebo in the treatment of mildly active UC.2' The major adverse effect in these preliminary clinical trials was loose or watery stools,27 which were observed only in 10% of patients. This complaint usually occurred in patients with extensively located colitis27 and might be explained by the action of the unsplit olsalazine molecule that, unlike sulphasalazine, markedly increases ileostomy output. 29 The efficacy of azoreduction in active disease is unknown, but indirect evidence points to a reduced azoreduction of sulphasalazine.9""' Among all it might be speculated that the intestinal transit time as well as the character of intestinal microflora depend on the extension and the severity of the disease and thus the distribution of olsalazine and its metabolites. This concept is supported by the present results showing that intolerance is associated with insufficient azoreduction. The increased incidence of diarrhoea observed in the present series most likely reflects the use of a higher dose of olsalazine than in a previous study.27Symptoms of this type of intolerance call, therefore, for a temporary reduction of the dose and the problem is more readily handled in clinical practice than in controlled trials with a fixed dose regimen. Also the occurrence of diarrhoea, which often subsided spontaneously with continued therapy, suggests that the therapeutic effect of 5-ASA may influence colonic function to permit a more effective azoreduction.
The present results also show that high doses of olsalazine can be administered safely in the long term and that azoreduction of olsalazine is almost complete in the major proportion of patients, even during administration of the highest dose (4 g/day). In this pharmaceutical respect, the olsalazine capsules fulfil the anticipation of providing a highly effective means of delivery of 5-ASA to the colonic mucosa, even in active disease. The results accord with our previous experience in patients with inactive UC and in healthy controls. 6 No other 'second generation" candidate reported on and developed to replace sulphasalazine -whether azobound or a pharmaceutically modified free 5-ASA preparation2232 -has hitherto been shown to provide colonic concentrations of 5-ASA in the same order of magnitude as those shown in the present study.
The findings of rather constant concentrations of Ac-5-ASA in faecal dialysates and dose dependently increasing concentrations of 5-ASA, indicate that saturation of the intraluminal acetylation capacity occurs at a low dosage. This may be clinically important, because a therapeutic effect of Ac-5-ASA has not been unequivocally established.9 4 The serum concentrations observed on olsalazine 1 g/day and 2 g/day are comparable with those reported in healthy controls.' 11 36 The results (Table  5) indicate a dose related increase in absorption of olsalazine and its metabolites, but do not suggest that cumulation occurs in the long term.
The demonstration of extremely high intraluminal levels of PGE2 in treatment failures accords with our previous findings '7 " and suggests that these quantifications of local disease activity are useful predictors of the outcome. We propose such determinations should be used prospectively in clinical trials on drug efficacy in UC.
The design of the present study did not permit any estimation of a dose response effect or a correlation between faecal 5-ASA levels and response to treatment. In planning the study we chose for safety reasons the pragmatic viewpoint to include only problematic' patients, who were not satisfactorily managed by conventional treatment -that is, sulphasalazine and a short course of glucocorticoid, although olsalazine may prove to be a sulphasalazine alternative. More treatment failures occurred among patients refractory to sulphasalazine than among patients intolerant of sulphasalazine. The complete splitting of olsalazine and the high concentrations of free 5-ASA in faecal dialysates from sulphasalazine refractory patients, who did not experience a remission, and from patients who relapsed, although maintained on a 4-g dose of olsalazine, indicate that sulphasalazine resistance is not merely a question of dosage, at least in a range up to 10 g/day -that is, equal to 4 g/day of olsalazine.
In conclusion, prolonged administration of high doses of olsalazine to patients with UC and CC appears acceptably well tolerated. The drug is a very effective means of delivery of 5-ASA to the colonic mucosa and, despite some cases of therapeutic resistance to even high intraluminal concentrations of 5-ASA, olsalazine seems to be a drug particularly appropriate for testing the efficacy of 5-ASA through controlled trials in patients with UC and CC in the long term. 
